The EU plans to postpone the implementation of certain provisions of the Artificial Intelligence Act.
According to Jinse Finance, the Financial Times reports that the European Commission, under significant pressure from major tech companies and the US government, has proposed suspending parts of its landmark artificial intelligence legislation. The EU plans to relax certain digital regulations in a decision called the "streamlining plan" on November 19. The EU has faced immense pressure on its AI Act from the US government, large tech companies, and European groups; the Act is considered the world's strictest regulatory framework for the development of artificial intelligence technology. A senior EU official stated that the EU has been in contact with the Trump administration regarding adjustments to the AI Act and other digital regulations. According to the draft, the EU is considering offering companies a one-year "grace period" for violations of the highest-risk AI usage rules, and also suggests postponing the implementation of fines for breaches of new AI transparency rules until August 2027. (Golden Ten Data)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Iranian President will head to New York for UN meeting
"Big Short" Burry opens a position in QXO (QXO.US), betting on building products integration and undervaluation; stock price rises over 7%
Investor Michael Burry disclosed that he has purchased common and preferred shares of QXO (QXO.US), a building products company, citing its integration strategy and the currently depressed stock price. The stock surged 7.2% on Monday.
700,000 new elderly patients join, Eli Lilly (LLY.US) dominates 70%: The first Medicare weight loss drug coverage report released
Dave Ricks, CEO of Eli Lilly (LLY.US), said in an interview on Monday that since Medicare began coverage for obesity drugs in July, 700,000 new elderly patients have started using GLP-1 medications.
Market Is Primed for a ‘Face Ripper' Rally Thanks to Four Ingredients Says Tom Lee
